RxDoctor Payments Data

Tod Haller, MD

Ophthalmology · Bronx, NYNPI 1740457548

Payments from drug & device makers

$1,869in general payments, 2019–2025

Across 85 payments — averaging $21.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$490
  • Sun Pharmaceutical Industries Inc.$461
  • Bausch & Lomb Americas Inc.$259
  • Oyster Point Pharma, Inc.$222
  • Amgen$104
  • Eyevance Pharmaceuticals LLC$104
  • plus $229 from 5 others

What the payments were for

  • Food & beverage$1,869100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,869 in reported general payments places this provider in the 55th percentile of 1,587 ophthalmology providers in New York.

See all ophthalmology providers in New York

Medicare billing

Part B allowed, 2024
$468,735
Medicare patients
719
Services billed
5,506

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine94$116,943
LumiganBimatoprost108$55,059
EysuvisLoteprednol Etabonate71$39,743
XiidraLifitegrast41$39,535
Loteprednol Etabonate120$29,334
RocklatanNetarsudil Mesylat/Latanoprost62$28,318
Cyclosporine34$17,198
ProlensaBromfenac Sodium39$14,608
CombiganBrimonidine Tartrate/Timolol32$12,508
Fluorometholone127$11,858
FlarexFluorometholone Acetate79$10,019
Bromfenac Sodium64$9,242
CequaCyclosporine16$8,805
RhopressaNetarsudil Mesylate24$7,904
ZyletTobramycin/Lotepred Etab12$7,435

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan$60$184,511234 claims
Bausch & Lomb Americas Inc.Xiidra, Vyzulta$259$44,17555 claims
Eyevance Pharmaceuticals LLCFlarex$104$10,01979 claims
Sun Pharmaceutical Industries Inc.Cequa$461$8,80516 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,587 ophthalmology providers in New York.

Other ophthalmology in Bronx

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →